## Table of Contents

### Highlights of This Issue 273

**REVIEW**

- **275** Targeting Microtubules by Natural Agents for Cancer Therapy  
  Eiman Mukhtar, Vaqar Mustafa Adhami, and Hasan Mukhtar

### SMALL MOLECULE THERAPEUTICS

- **285** Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer  

- **297** Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines  
  Marie R. Webster, Chandrashekhar Kamat, Nick Connis, Ming Zhao, Ashani T. Weeraratna, Michelle A. Rudek, Christine L. Hann, and Caren L. Freel Meyers

- **307** Selective Inhibition of Pancreatic Ductal Adenocarcinoma Cell Growth by the Mitotic MPS1 Kinase Inhibitor NMS-P715  
  Roger B. Sleet, Brenda R. Grimes, Ruchi Bansal, Jesse Gore, Corinne Blackburn, Lyndsey Brown, Rachel Gasaway, Jaseek Jeong, Jose Victorino, Keith L. March, Ricardo Colombo, Brittney-Shea Herbert, and Murray Korc

### LARGE MOLECULE THERAPEUTICS

- **341** A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells  
  Karishma S. Amin, Shankar Jagadeesh, Gakul Baishya, Paruchuri G. Rao, Nabin C. Barua, Samir Bhattacharya, and Partha P. Banerjee

- **353** Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespiib  
  Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates, and David A. Proia

- **364** Characterization of LY228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity  

### REVIEW

- **375** Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation  
  Manuel Simon, Nikolas Stefan, Lubor Borsig, Andreas Pluckthun, and Uwe Zangemeister-Wittke

- **386** Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling  
Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy
Kohei Sano, Takahito Nakajima, Peter L. Choyke, and Hisataka Kobayashi

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junio Murai, Shar-Yin N. Huang, Amelie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow, and Yves Pommier

MiR-134/487b/655 Cluster Regulates TGF-β-Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAM2 in Lung Adenocarcinoma Cells
Kazuhito Kitamura, Masahiro Seike, Tetsuya Okano, Kuniko Matsuda, Akihiko Miyatake, Hideoki Mizutani, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, and Akihiko Gemma

OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice
Dilek Iusuf, Marion Ludwig, Ahmed Elbatsi, Ania van Esch, Evita van de Steeg, Els Wagenaar, Martin van der Valk, Fan Lin, Olaf van Tellingen, and Alfred H. Schinkel

Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Xi Chen, Elena Díaz-Rodríguez, Enrique M. Ocío, Bruno Paiva, Deborah S. Mortensen, Antonio Lopez-Girona, Rajesh Chopra, Jesús San Miguel, and Atanasio Pandiella

Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235’s Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Yu Wang, Qi Yu, Xin He, Todd Romigh, Jessica Altemus, and Charis Eng

Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Yan Ning, Armin Gerger, Wu Zhang, Diana L. Hanna, Dongyun Yang, Thomas Winder, Takeru Wataatsuki, Melissa J. Labonte, Sebastian Stintzing, Nico Volz, Yu Sunakawa, Stefan Stremitzer, Rita El-Khoueiry, and Heinz-Josef Lenz
Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant, and Judy C. Young

Correction: Aerosol Delivery of Urocanic Acid–Modified Chitosan/Programmed Cell Death 4 Complex Regulated Apoptosis, Cell Cycle, and Angiogenesis in Lungs of K-ras Null Mice

ABOUT THE COVER
The ALK/MET inhibitor crizotinib has already shown efficacy in ALK-driven non–small cell lung cancer patients, but the treatment is not curative with rapid acquisition of resistance, which is partly attributable to the gatekeeper-residue mutation L1196M of ALK. Computational modeling suggested that ASP3026, a novel small molecule ALK inhibitor, is well docked with both wild-type and L1196M ALK, and fits more deeply within the ATP-binding pocket of the L1196M form, with the larger side-chain of methionine compared to leucine, than crizotinib. This might explain why ASP3026 showed more potent efficacy against the L1196M mutant within the therapeutic margin compared with crizotinib. For details, see article by Mori and colleagues, on page 329.